Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond

The advent of mitogen-activated protein kinase (MAPK) inhibitors that directly inhibit tumor growth and of immune checkpoint inhibitors (ICI) that boost effector T cell responses have strongly improved the treatment of metastatic melanoma. In about half of all melanoma patients, tumor growth is driven by gain-of-function mutations of BRAF (v-rat fibrosarcoma (Raf) murine sarcoma viral oncogene homolog B), which results in constitutive ERK activation. Patients with a BRAF mutation are regularly treated with a combination of BRAF and MEK (MAPK/ERK kinase) inhibitors. Next to the antiproliferative effects of BRAF/MEKi, accumulating preclinical evidence suggests that BRAF/MEKi exert immunomodulatory functions such as paradoxical ERK activation as well as additional effects in non-tumor cells. In this review, we present the current knowledge on the immunomodulatory functions of BRAF/MEKi as well as the non-intended effects of ICI and discuss the potential synergistic effects of ICI and MAPK inhibitors in melanoma treatment.

[1]  V. Sarathy,et al.  Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research , 2021, Frontiers in Oncology.

[2]  R. Matkowski,et al.  Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance , 2021, Cells.

[3]  M. Rosanova,et al.  BRAF Gene and Melanoma: Back to the Future , 2021, International journal of molecular sciences.

[4]  Y. Tada,et al.  Edoxaban prevented adverse effects including pyrexia and elevation of D‐dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF‐mutant melanoma , 2021, The Journal of dermatology.

[5]  C. Lebbé,et al.  New perspectives on targeting RAF, MEK and ERK in melanoma , 2020, Current opinion in oncology.

[6]  K. Flaherty,et al.  Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Katie M. Campbell,et al.  PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma , 2020, Nature Communications.

[8]  H. Kono,et al.  Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks , 2020, Genes.

[9]  A. Pitt,et al.  Approaches to Investigating the Protein Interactome of PTEN. , 2020, Journal of proteome research.

[10]  D. Schadendorf,et al.  Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i , 2020, Nature Medicine.

[11]  C. Garbe,et al.  Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients , 2020, Cancers.

[12]  K. Rajalingam,et al.  The non-linearity of RAF-MEK signaling in dendritic cells , 2020, Cell cycle.

[13]  I. Proietti,et al.  BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions , 2020, Cancers.

[14]  P. Rutkowski,et al.  Targeted Therapy in Melanoma and Mechanisms of Resistance , 2020, International journal of molecular sciences.

[15]  D. Jeoung,et al.  Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma , 2020, Frontiers in Cell and Developmental Biology.

[16]  J. Geisler,et al.  BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis , 2020, Acta oncologica.

[17]  M. Tambuwala,et al.  Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. , 2020, International immunopharmacology.

[18]  Aaron White,et al.  Current Advances in the Treatment of BRAF-Mutant Melanoma , 2020, Cancers.

[19]  D. Schadendorf,et al.  Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. , 2020, European journal of cancer.

[20]  Jiancheng Hu,et al.  Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy , 2020, Cells.

[21]  C. Lebbé,et al.  Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. , 2019, Current opinion in oncology.

[22]  Kimberly J. Johnson,et al.  Melanoma in individuals with neurofibromatosis type 1: a retrospective study. , 2019, Dermatology online journal.

[23]  S. McGregor,et al.  Update on Current Treatment Recommendations for Primary Cutaneous Melanoma. , 2019, Dermatologic clinics.

[24]  H. Schild,et al.  RAF kinases are stabilized and required for dendritic cell differentiation and function , 2019, Cell Death & Differentiation.

[25]  R. Fisher,et al.  Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma , 2019, Nature Medicine.

[26]  James X. Sun,et al.  Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings , 2019, Expert opinion on drug safety.

[27]  Kwok-Kin Wong,et al.  Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer , 2019, Cell reports.

[28]  T. Kanneganti,et al.  Diverging inflammasome signals in tumorigenesis and potential targeting , 2019, Nature Reviews Cancer.

[29]  P. Savoia,et al.  Targeting the ERK Signaling Pathway in Melanoma , 2019, International journal of molecular sciences.

[30]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  C. Jung,et al.  Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes , 2018, Cancers.

[32]  B. Hernando,et al.  In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants , 2018, Pigment cell & melanoma research.

[33]  C. Praetorius,et al.  Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy , 2018, Pharmacological research.

[34]  M. Bros,et al.  Interleukin-1 Beta—A Friend or Foe in Malignancies? , 2018, International journal of molecular sciences.

[35]  P. Ascierto,et al.  Immunological effects of BRAF+MEK inhibition , 2018, Oncoimmunology.

[36]  T. Curiel,et al.  Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. , 2018, Cancer research.

[37]  I. Steinmetz,et al.  BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells , 2018, Oncotarget.

[38]  R. Sullivan.  The role of targeted therapy for melanoma in the immunotherapy era , 2018, Seminars in cutaneous medicine and surgery.

[39]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[40]  Liang Cheng,et al.  Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine , 2017, Modern Pathology.

[41]  M. Therrien,et al.  RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition , 2017, Nature Communications.

[42]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[43]  Ling Peng,et al.  Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis , 2017, Oncotarget.

[44]  Zhi Wei,et al.  PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas , 2017, Nature.

[45]  Haidong Dong,et al.  Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells , 2017, Front. Immunol..

[46]  J. Pérez-García,et al.  NRAS-mutant melanoma: current challenges and future prospect , 2017, OncoTargets and therapy.

[47]  C. Wellbrock,et al.  Overcoming resistance to BRAF inhibitors. , 2017, Annals of translational medicine.

[48]  K. Flaherty,et al.  An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition , 2017, The Journal of experimental medicine.

[49]  Rebecca F. Halperin,et al.  Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. , 2017, Genome research.

[50]  D. Schadendorf,et al.  Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  K. Busam,et al.  The NF1 gene in tumor syndromes and melanoma , 2017, Laboratory Investigation.

[52]  M. Mandalà,et al.  Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation , 2017, Laboratory Investigation.

[53]  M. Herlyn,et al.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. , 2016, Cancer cell.

[54]  P. Lacal,et al.  Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. , 2016, International journal of oncology.

[55]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[56]  E. Martínez-Balibrea,et al.  Resistant mechanisms to BRAF inhibitors in melanoma. , 2016, Annals of translational medicine.

[57]  J. Fisher,et al.  The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells , 2016, Melanoma research.

[58]  K. Strebhardt,et al.  Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy , 2016, Oncogene.

[59]  B. Bastian,et al.  From melanocytes to melanomas , 2016, Nature Reviews Cancer.

[60]  C. Figdor,et al.  Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition , 2016, Journal of Translational Medicine.

[61]  J. Larkin,et al.  Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations , 2016, Expert opinion on pharmacotherapy.

[62]  M. Belvin,et al.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.

[63]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[64]  Alison White,et al.  FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor , 2015, Pathology.

[65]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[66]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[67]  Erik Sahai,et al.  Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.

[68]  P. Hwu,et al.  BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma , 2015, Cancer Immunology Research.

[69]  T. Graeber,et al.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma , 2015, Science Translational Medicine.

[70]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[71]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Herlyn,et al.  BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth , 2015, Clinical Cancer Research.

[73]  J. Wilmott,et al.  PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients , 2015, Clinical Cancer Research.

[74]  L. Tsvetkov,et al.  The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 , 2015, Clinical Cancer Research.

[75]  K. Flaherty,et al.  The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. , 2014, Cancer discovery.

[76]  C. Parkinson,et al.  Management of melanoma. , 2014, British medical bulletin.

[77]  S. Kaech,et al.  Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. , 2014, Cancer research.

[78]  B. Taylor,et al.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.

[79]  J. Wilmott,et al.  Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment , 2014, The Journal of Immunology.

[80]  J. Utikal,et al.  Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. , 2014 .

[81]  J. Cebon,et al.  MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells , 2014, Cancer Immunology Research.

[82]  J. Wolchok,et al.  Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor , 2013, Cancer Immunology Research.

[83]  J. Arthur,et al.  Mitogen-activated protein kinases in innate immunity , 2013, Nature Reviews Immunology.

[84]  B. Schilling,et al.  Immunological consequences of selective BRAF inhibitors in malignant melanoma , 2013, Oncoimmunology.

[85]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[86]  P. Ott,et al.  Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties , 2013, Cancer Immunology, Immunotherapy.

[87]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[88]  Dennie T. Frederick,et al.  Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma , 2012, Clinical Cancer Research.

[89]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[90]  T. Golub,et al.  Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion , 2012, Nature.

[91]  Gang Li,et al.  Genetic alterations of PTEN in human melanoma , 2012, Cellular and Molecular Life Sciences.

[92]  Takami Sato,et al.  Interleukin 6 mediates production of interleukin 10 in metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.

[93]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[94]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[95]  A. Aplin,et al.  Mechanisms of resistance to RAF inhibitors in melanoma , 2011, The Journal of investigative dermatology.

[96]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[97]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[98]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[99]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[100]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[101]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[102]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[103]  F. Lozupone,et al.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.

[104]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[105]  Rui Qiao,et al.  BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. , 2003, Cancer research.

[106]  C. Garbe,et al.  Epidemiology of Skin Cancer: Update 2019. , 2020, Advances in experimental medicine and biology.

[107]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[108]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .